These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 31886876)

  • 1. Prognostic model for multiple myeloma progression integrating gene expression and clinical features.
    Sun C; Li H; Mills RE; Guan Y
    Gigascience; 2019 Dec; 8(12):. PubMed ID: 31886876
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Survival prediction and treatment optimization of multiple myeloma patients using machine-learning models based on clinical and gene expression data.
    Mosquera Orgueira A; González Pérez MS; Díaz Arias JÁ; Antelo Rodríguez B; Alonso Vence N; Bendaña López Á; Abuín Blanco A; Bao Pérez L; Peleteiro Raíndo A; Cid López M; Pérez Encinas MM; Bello López JL; Mateos Manteca MV
    Leukemia; 2021 Oct; 35(10):2924-2935. PubMed ID: 34007046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Pattern of Mesenchymal Stem Cell Expression Is an Independent Marker of Outcome in Multiple Myeloma.
    Schinke C; Qu P; Mehdi SJ; Hoering A; Epstein J; Johnson SK; van Rhee F; Zangari M; Thanendrarajan S; Barlogie B; Davies FE; Yaccoby S; Morgan GJ
    Clin Cancer Res; 2018 Jun; 24(12):2913-2919. PubMed ID: 29563136
    [No Abstract]   [Full Text] [Related]  

  • 4. Identification and Validation of a Potential Prognostic 7-lncRNA Signature for Predicting Survival in Patients with Multiple Myeloma.
    Zhong Y; Liu Z; Li D; Liao Q; Li J
    Biomed Res Int; 2020; 2020():3813546. PubMed ID: 33204693
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Gene expression profiles of tumor biology provide a novel approach to prognosis and may guide the selection of therapeutic targets in multiple myeloma.
    Anguiano A; Tuchman SA; Acharya C; Salter K; Gasparetto C; Zhan F; Dhodapkar M; Nevins J; Barlogie B; Shaughnessy JD; Potti A
    J Clin Oncol; 2009 Sep; 27(25):4197-203. PubMed ID: 19636021
    [TBL] [Abstract][Full Text] [Related]  

  • 6.
    Zhong H; Huang D; Wu J; Chen X; Chen Y; Huang C
    BMC Med Imaging; 2023 Jun; 23(1):87. PubMed ID: 37370013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete hazard ranking to analyze right-censored data: An ALS survival study.
    Huang Z; Zhang H; Boss J; Goutman SA; Mukherjee B; Dinov ID; Guan Y;
    PLoS Comput Biol; 2017 Dec; 13(12):e1005887. PubMed ID: 29253881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification of Key Genes and Pathways in Myeloma side population cells by Bioinformatics Analysis.
    Yang Q; Li K; Li X; Liu J
    Int J Med Sci; 2020; 17(14):2063-2076. PubMed ID: 32922167
    [No Abstract]   [Full Text] [Related]  

  • 9. Gene expression risk signatures maintain prognostic power in multiple myeloma despite microarray probe set translation.
    Hermansen NE; Borup R; Andersen MK; Vangsted AJ; Clausen NT; Kristensen DL; Nielsen FC; Gimsing P
    Int J Lab Hematol; 2016 Jun; 38(3):298-307. PubMed ID: 27027250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gene Expression Analysis of the Bone Marrow Microenvironment Reveals Distinct Immunotypes in Smoldering Multiple Myeloma Associated to Progression to Symptomatic Disease.
    Isola I; Brasó-Maristany F; Moreno DF; Mena MP; Oliver-Calders A; Paré L; Rodríguez-Lobato LG; Martin-Antonio B; Cibeira MT; Bladé J; Rosiñol L; Prat A; Lozano E; Fernández de Larrea C
    Front Immunol; 2021; 12():792609. PubMed ID: 34880879
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-risk identification in multiple myeloma using a new 14-gene model.
    Chen T; Berno T; Zangari M
    Eur J Haematol; 2012 Jul; 89(1):28-36. PubMed ID: 22620863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gene expression profiling in multiple myeloma--reporting of entities, risk, and targets in clinical routine.
    Meissner T; Seckinger A; Rème T; Hielscher T; Möhler T; Neben K; Goldschmidt H; Klein B; Hose D
    Clin Cancer Res; 2011 Dec; 17(23):7240-7. PubMed ID: 21986844
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of key miRNA signature and pathways involved in multiple myeloma by integrated bioinformatics analysis.
    Dong X; Lu G; Su X; Liu J; Chen X; Tian Y; Chang Y; Wang L; Wang W; Zhou J
    Hematology; 2021 Dec; 26(1):976-984. PubMed ID: 34871535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The reconstruction of transcriptional networks reveals critical genes with implications for clinical outcome of multiple myeloma.
    Agnelli L; Forcato M; Ferrari F; Tuana G; Todoerti K; Walker BA; Morgan GJ; Lombardi L; Bicciato S; Neri A
    Clin Cancer Res; 2011 Dec; 17(23):7402-12. PubMed ID: 21890453
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification and validation of potential prognostic lncRNA biomarkers for predicting survival in patients with multiple myeloma.
    Zhou M; Zhao H; Wang Z; Cheng L; Yang L; Shi H; Yang H; Sun J
    J Exp Clin Cancer Res; 2015 Sep; 34(1):102. PubMed ID: 26362431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gene signature combinations improve prognostic stratification of multiple myeloma patients.
    Chng WJ; Chung TH; Kumar S; Usmani S; Munshi N; Avet-Loiseau H; Goldschmidt H; Durie B; Sonneveld P
    Leukemia; 2016 May; 30(5):1071-8. PubMed ID: 26669975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Centrosome associated genes pattern for risk sub-stratification in multiple myeloma.
    Kryukov F; Nemec P; Radova L; Kryukova E; Okubote S; Minarik J; Stefanikova Z; Pour L; Hajek R
    J Transl Med; 2016 May; 14(1):150. PubMed ID: 27234807
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of A-Kinase Interacting Protein 1 With Clinical Features, Treatment Response, and Survival Profiles in Patients With Multiple Myeloma.
    Wang W; Xie Y; Han X; Liu Y; Li P
    Technol Cancer Res Treat; 2020; 19():1533033820935856. PubMed ID: 32799782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials.
    Bhutani M; Zhang Q; Friend R; Voorhees PM; Druhan LJ; Barlogie B; Sonneveld P; Morgan GJ; Symanowski JT; Avalos BR; Copelan EA; Usmani SZ
    Lancet Haematol; 2017 Sep; 4(9):e443-e451. PubMed ID: 28863804
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic Validation of SKY92 and Its Combination With ISS in an Independent Cohort of Patients With Multiple Myeloma.
    van Beers EH; van Vliet MH; Kuiper R; de Best L; Anderson KC; Chari A; Jagannath S; Jakubowiak A; Kumar SK; Levy JB; Auclair D; Lonial S; Reece D; Richardson P; Siegel DS; Stewart AK; Trudel S; Vij R; Zimmerman TM; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):555-562. PubMed ID: 28735890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.